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Adipose tissue secretes molecules that can promote activity in Crohn’s disease. We aimed to evaluate 
the role of serum adipokines as possible biomarkers in Crohn’s disease. Serum samples were obtained 
from 40 patients with endoscopically active or quiescent Crohn’s disease and 36 healthy controls. 
Serum leptin, ghrelin, resistin and adiponectin levels were analysed by Multiplex in a Luminex 
200 system technology. Receiver Operating Characteristic curves were performed to evaluate the 
adipokines discriminatory capacity. A logistic regression adjusted by possible confounders (i.e. 
gender, age, BMI) was performed for those adipokines that showed an area under the curve > 0.7. 
No differences were found in age, gender or BMI among groups. Distribution for serum resistin was 
different among the three groups of study, and only this adipokine showed an area under the curve 
of 0.75 comparing actives patients and healthy control groups. Resistin median concentration was 
selected as a cut‑off for a logistic regression analysis; odds ratio along its 95% confidence interval 
adjusted by gender, age, and BMI yielded a value of 5.46 (1.34–22.14) comparing actives patients and 
healthy controls. High concentration of serum resistin is probably associated to activity, being this 
association independent of gender, age or BMI.
Abbreviations
aCD  Active Crohn’s disease
qCD  Quiescent Crohn’s disease
CD  Crohn’s disease
IBD  Inflammatory bowel disease
HC  Healthy control
SES-CD  Simple Endoscopic Score for Crohn’s Disease
ROC  Receiver operating characteristic
AUC  Area under the curve
Inflammatory bowel disease (IBD) is a pathology associated to Occidentalized countries. However, its incidence 
is currently increasing over the world and it may become a global  disease1. Hence, the cost to the Public Health 
System has been incremented due to its chronicity and the early aged-onset of this  pathology2–4. IBD is classified 
in two different entities named Crohn’s disease (CD) and ulcerative colitis that are characterized by a chronic 
inflammation of the gastrointestinal tract. While ulcerative colitis is only limited to the colon, CD may come 
along with extra intestinal  manifestations5. Under this scenario, it is necessary to find new strategies for the 
improvement of IBD patients’ quality of life.
Visceral adipose tissue is a risk factor for pathologies like diabetes mellitus type 2 and cardiovascular  disease6, 
but also for CD where it increases its grade of  inflammation7. Indeed, there is a mesenteric adipose tissue 
enlargement in CD, known as creeping fat8 where inflamed intestinal zones show increased numbers of small 
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size adipocytes and immune  cells9. This creeping fat can modulate the immune system inducing an inflammatory 
response by secretion of several adipokines including leptin, adiponectin or  resistin10.
Leptin is an adipokine secreted by adipocytes which stimulates the production of pro-inflammatory IL-1β 
and IL-6 in T  cells11. Adiponectin is secreted from adipocytes and displays anti-inflammatory  properties12. On 
the other hand, resistin is an adipokine upregulated in the mesenteric adipose tissue from  CDpatients11 which 
may act as an independent predictor of disease in  CD13. Ghrelin is an endogenous ligand of the growth hormone 
secretagogue  receptor14 and anorexigenic peptide with anti-inflammatory  activity15 reason why it may also be 
marker of disease activity in  CD16.
Despite the role that adipokines and the lipid metabolism elicit in CD pathogenesis, to our knowledge few 
studies explored them as non-invasive biomarkers to assess mucosal status in patients with endoscopically 
inflamed or active CD (aCD) and non-inflamed or quiescent disease (qCD). Our aim therefore was to analyse 
the adipokine serum profile in CD patients and healthy controls (HC) in order to get a deeper insight into their 
contribution towards CD pathogenesis and to assess CD mucosal status (quiescent or active)in the absence of 
a colonoscopy.
Results
Descriptional study. There were no differences in gender, age and BMI among study groups (Table 1). 
Following exclusion of the samples with levels above or under detection limits, a total of 2 HC were removed. 
Results from the 74 remaining individuals are shown in Table 2. Median comparisons of the adipokines con-
centrations (natural log transformed) among groups were only statistically significant in the case of resistin 
(p = 0.04) (Table 2), while Dunn test post hoc analysis revealed that this was due to the comparison between aCD 
and HC (p = 0.03). No correlation was found among the four serum adipokines levels (Fig. 1).
Discriminatory power of adipokines. The discriminatory power of leptin, adiponectin, ghrelin and 
resistin between the study groups was tested by ROC curves. AUC was below of 0.7 for comparisons between 
qCD and HC (Fig. 2a, Table 3a), but also between aCD and qCD (Fig. 2b, Table 3b). The discriminatory power 
of each adipokine between aCD and HC, was also tested by ROC curves analysis, and the AUC was above 0.7 
only for resistin (Fig. 2c), AUC along with its 95% confidence interval was 0.75 (0.61–0.89), comparing aCD and 
HC (Table 3c). Following with this analysis, Youden cut-off index for ROC curve (Fig. 3) matched with the total 
resistin median concentration (9822 pg/ml), so this value worked as a cut-off for subsequent regression analysis 
between resistin and CD activity, which showed a strong association, odds ratio (OR) along with its 95% confi-
dence interval was 5.46 (1.34–22.14) adjusted by gender, age and BMI; thus, patients with a resistin concentra-
tion above 9822 pg/ml may be candidates for developing activity.
Discussion
Creeping fat and mesenteric adipose tissue are characteristic of  CD17. Indeed, this adipose tissue has the capacity 
to produce several adipokines which participate in the intestinal inflammatory  response18. In this regard, and in 
order to get a deeper insight into their contribution towards IBD pathogenesis, we decided to study their serum 
levels in CD patients, both endoscopically active and quiescent. Hence, our results describe how high resistin 
serum levels are associated with endoscopically active (inflamed) CD patients.
Table 1.  Baseline characteristics in the study cohort (n = 76). Continuous variables were reported as 
mean ± SD. Chi square test and means comparisons were performed. HC healthy control, qCD quiescent CD, 
aCD active CD, BMI body mass index.
Variable HC (36) qCD (22) aCD (18) p
Age(years) 51.4 ± 15.1 46.5 ± 12.2 44.4 ± 13.2 0.2
BMI 24.4 ± 3.9 24.1 ± 4.6 26.4 ± 3.4 0.1
Males(n, %) 16, 44.4 11, 50 8, 44.4 0.9
Table 2.  Adipokines concentration in the groups of the study and Kruskal–Wallis comparison (n = 74). 
Variables were reported as median (interquartile range); Kruskal–Wallis comparisons were performed. In the 
case of resistin, Dunn test post hoc analysis was significant only for HC vs. aCD(p = 0.03). Only those patients 
with data for the four adipokines variables were considered. All variables were natural log transformed before 
the analysis. HC healthy control, qCD quiescent CD, aCD active CD.
Molecule(pg/ml) HC (34) qCD (22) aCD (18) p
Adiponectin 17.7 (17.1–17.8) 17.7 (17.6–17.8) 17.7 (17.6–17.8) 0.3
Resistin 9.0 (8.8–9.3) 9.2 (8.9–9.5) 9.3 (9.2–9.7) 0.04
Leptin 7.8 (6.8–9.0) 7.5 (6.4–8.7) 7.9 (6.7–8.7) 0.9
Ghrelin 4.6 (4.0–6.3) 4.8 (3.9–5.5) 3.9 (3.6–5.4) 0.07
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Figure 1.  Spearman correlations for adipokines.
Figure 2.  (a) Receiving operating characteristic curves for leptin, ghrelin, adiponectin and resistin comparing 
patients with quiescent Crohn’s disease (qCD) and healthy controls (HC). (b) Receiving operating characteristic 
curves for leptin, ghrelin, adiponectin and resistin comparing patients with quiescent Crohn’s disease (qCD) and 
active Crohn’s disease (aCD). (c) Receiving operating characteristic curves for leptin, ghrelin, adiponectin and 
resistin comparing patients with active Crohn’s disease (aCD) and healthy controls (HC).
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So far, studies of association among adipokines and IBD are contrasting. Leptin has been described 
 asincreased19,  reduced20 and even  unaltered21 in IBD patients. In this regard, and although leptin acts as a 
proinflammatory adipokine, results in clinical studies about its role in IBD pathogenesis are ambiguous and, in 
agreement with our findings, several studies found that it was not related to  IBD21,22.
Results regarding adiponectin involvement in IBD pathogenesis are also  divergent12,23. This adipokine is 
characterized by anti-inflammatory properties and its concentration decreases in  obesity24. However, adiponectin 
has been associated to cardiovascular mortality in patients with type 2 diabetes playing a paradoxical role as the 
higher concentration of adiponectin the higher is the risk of cardiovascular  mortality25,26. Here, there was no 
association with activity in CD and further studies are necessary to test its role in CD.
Ghrelin has been introduced as an orexigenic peptide, being our results in the line of those from Nishi et al. 
who did not show any change in serum ghrelin in CD  patients21.
Resistin, on the contrary, is an adipokine that participates in several inflammatory processes. Indeed, it has 
been associated with impairment of type 2 diabetes and  atherosclerosis27. In our study, resistin showed an asso-
ciation with disease activity in CD regardless of the small size of the data cohort. Hence, our results suggest that 
this adipokine could play an important role in IBD pathogenesis at the time that its serum levels could have a 
role as a non-invasive biomarker to assess mucosal status of CD patients in the absence of a colonoscopy.
Table 3.  Receiving operating characteristic statistics. AUC area under the curve along with their 95% 



















Figure 3.  Youden indexfor resistin in the receiving operating curve comparing patients with active Crohn’s 
disease (aCD) and healthy controls (HC).
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Obesity has been associated with IBD prevalence being more common in CD than in ulcerative colitis. How-
ever, how obesity affects the development of the pathology has not been elucidated  yet28. The Nurses’ Health 
Study, from USA, revealed that obesity assessed by BMI was associated with a higher risk of CD than ulcerative 
 colitis29. In our study, there are no significant differences among groups when BMI was compared.
We are aware about the limitations of our study as given the restricted sample size of our cohort; we could 
not find important differences due to the lack of power. Another limitation is the absence of measures regarding 
visceral adipose tissue, reason why we used BMI as a measure of total fat. Our results reinforce the role of resistin 
as a possible biomarker of disease activity in CD and a novel target to elucidate CD pathogenesis.
Further studies should complement our approach including larger and independent cohorts, as well the 
measure of visceral adipose tissue in order to investigate how resistin, and other adipokines, might lead to an 
inflamed state in CD and to unravel new functions of serum adipokines which could work as serum biomarkers 
of endoscopic activity in CD.
Conclusion
We analyze here four adipokines that have been associated with inflammation and chronic diseases along the 
literature. Our aim was to elucidate if they are able to work as biomarkers of activity in CD. Among them, only 
high serum resistin levels seems to be associated with activity in CD. Resistin would be a candidate for future 
studies of association with activity regarding this type of IBD. It is necessary to analyze this molecule in an inde-
pendent and larger cohort in the future to test its capacity as biomarker of inflamed state in CD.
Methods
A total of 76 human serum samples were analyzed. The biological samples used in this project were obtained 
from the Collection of Biological Samples of Dr. Javier P. Gisbert, which is registered in the National Biobanks 
Registry of Instituto de Salud Carlos III (C.0003482), Madrid, Spain. The study protocols and the informed con-
sent procedures were approved by the Institutional Ethic Committee of Hospital Universitario de La Princesa, 
Madrid, Spain. All participants in the study gave written informed consent. All methods were carried out in 
accordance with the approved guidelines.
All serum samples were obtained from CD patients and HC at the moment of colonoscopy. The Simple 
Endoscopic Score for Crohn’s Disease (SES-CD) was determined during colonoscopy in all CD patients in order 
to classify them as aCD (SES-CD ≥ 3) or qCD (SES-CD ≤ 2). All colonoscopies were performed in the context of 
the normal clinical practice for CD diagnose or monitoring. Inclusion criteria for patients with CD were patients 
older than 18 years old diagnosed with CD according to European Crohn’s and Colitis Organisation criteria and 
did not meet one or more exclusion criteria. Exclusion criteria for patients with CD were the following: to have 
received immunosuppressive treatment for any pathology other than IBD; to have an immune-mediated disease, 
different from IBD; to have a neoplasm or an active infection at the time of the colonoscopy; to be pregnancy or 
lactation at the moment of the colonoscopy.
HC were referred to colonoscopy due to changes in the bowel transit, rectal bleeding or colorectal cancer 
screening. However, in all cases they had normal (non-inflamed) intestinal mucosa and had not known inflam-
matory processes, autoimmune diseases or malignancies, not pregnancy nor lactation and without any infectious 
diseases at the moment of the colonoscopy.
Serum samples were obtained following blood centrifugation, aliquoted and immediately cryopreserved 
at − 80 °C. Samples had not been defrosted before the experiment to make sure that all of them were analysed 
in the same conditions. Samples from a total of 36 HC, 18 patients with aCD and 22 patients with qCD were 
analysed. Patients’ information regarding gender, age, ethnic background (all of them were caucasians) and BMI 
were collected in a codified manner from medical records. Demographic variables (i.e. gender, age and BMI) 
were analysed by chi square test (frequencies) or ANOVA test (means).
Adipokines from serum samples were analysed by duplicated using Bio-PlexPro Human Diabetes group 
(leptin, ghrelin and resistin) and Bio-plexPro Hu Diab Adiponectin (adiponectin) from Bio-Rad (Hércules, 
CA, USA), in a Luminex200 System technology. Samples were processed following manufacturer’s instructions. 
The final concentration value of each adipokine was the result of the mean from the two duplicated measures. 
Adipokines concentrations above or below the kit sensitivity range were not considered. Skewness was tested 
by Kolgomorov–Smirnov test. Adipokines levels were all natural log transformed. Spearman correlation was 
performed for the adipokines. Median and interquartile range for each patient group was determined for the 
adipokines and Kruskal–Wallis test was performed. Receiver Operating Characteristic (ROC) curves and the 
area under the curve (AUC) were carried out to evaluate the discriminatory capacity of the adipokines levels 
comparing different study groups. The Youden cut-off index got from the ROC curve was analysed. Furthermore, 
those adipokines that showed an AUC > 0.7 along their 95% confidence interval were selected for a binary logistic 
regression adjusted by possible confounders (i.e. gender, age, BMI) in order to test their possible association with 
CD. All statistical analyses were carried out in SPSS v15, SAS University Edition and R.
Data availability
Datasets are available from the corresponding author on reasonable request.
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